CEBPA and neoplasm: These findings highlight the safety and anti-tumor potential of JCXH-211.Additionally, clinical trials investigating MTL-CEBPA, a small activating RNA (saRNA), in combination with pembrolizumab (ClinicalTrials.gov Identifier: NCT04105335) and atezolizumab (ClinicalTrials.gov Identifier: NCT05097911) for advanced solid tumors are ongoing.